HIA
BEAM icon

HFM Investment Advisors’s Beam Therapeutics BEAM Stock Holding History

HFM Investment Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$172 Buy
5
+4
+400% +$121 ﹤0.01% 1195
2026
Q1 		$24 Hold
1
– – ﹤0.01% 1192
2025
Q4 		$28 Hold
1
– – ﹤0.01% 1255
2025
Q3 		$24 Hold
1
– – ﹤0.01% 1247
2025
Q2 		$17 Hold
1
– – ﹤0.01% 1270
2025
Q1 		$20 Buy
+1
New +$26 ﹤0.01% 1150

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

HFM Investment Advisors's BEAM Position: Q2 2026 in Review

HFM Investment Advisors increased its Beam Therapeutics (BEAM) stake by 400% in Q2 2026, buying an estimated $121 and bringing the position to 5 shares worth $172. The position accounts for ﹤0.01% of the portfolio, ranked #1195.

HFM Investment Advisors first reported a position in BEAM in Q1 2025 and has held it in 6 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • HFM Investment Advisors held 5 shares of Beam Therapeutics worth $172 as of Q2 2026.
  • HFM Investment Advisors bought 4 Beam Therapeutics shares in Q2 2026, an estimated $121.
  • Beam Therapeutics made up ﹤0.01% of HFM Investment Advisors's portfolio in Q2 2026, its #1195 holding.
  • HFM Investment Advisors first reported a position in Beam Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on HFM Investment Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.